Strategic Blueprint LLC trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 26.2% within the third quarter, in line with the corporate in its most up-to-date Kind 13F submitting with the Securities & Alternate Fee. The fund owned 12,182 shares of the biopharmaceutical firm’s inventory after promoting 4,314 shares in the course of the interval. Strategic Blueprint LLC’s holdings in Bristol-Myers Squibb had been value $630,000 as of its most up-to-date SEC submitting.
Different hedge funds and different institutional traders have additionally modified their holdings of the corporate. ESL Belief Providers LLC bought a brand new stake in Bristol-Myers Squibb in the course of the first quarter valued at about $27,000. ORG Wealth Companions LLC bought a brand new stake in shares of Bristol-Myers Squibb within the third quarter valued at roughly $34,000. LGT Monetary Advisors LLC boosted its stake in Bristol-Myers Squibb by 42.7% within the 2nd quarter. LGT Monetary Advisors LLC now owns 759 shares of the biopharmaceutical firm’s inventory value $32,000 after buying a further 227 shares in the course of the interval. MFA Wealth Advisors LLC bought a brand new place in Bristol-Myers Squibb in the course of the 2nd quarter value roughly $39,000. Lastly, Seashore Funding Counsel Inc. PA acquired a brand new stake in Bristol-Myers Squibb in the course of the 2nd quarter valued at $42,000. Institutional traders and hedge funds personal 76.41% of the corporate’s inventory.
Bristol-Myers Squibb Inventory Up 0.3 %
Bristol-Myers Squibb inventory opened at $52.68 on Thursday. The corporate has a present ratio of 1.16, a fast ratio of 1.02 and a debt-to-equity ratio of two.86. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year excessive of $55.03. The agency’s fifty day easy transferring common is $50.98 and its 200-day easy transferring common is $46.48. The corporate has a market capitalization of $106.79 billion, a P/E ratio of -16.99, a P/E/G ratio of 13.75 and a beta of 0.46.
Bristol-Myers Squibb Dividend Announcement
The enterprise additionally not too long ago declared a quarterly dividend, which can be paid on Friday, November 1st. Shareholders of report on Friday, October 4th can be given a $0.60 dividend. The ex-dividend date is Friday, October 4th. This represents a $2.40 dividend on an annualized foundation and a dividend yield of 4.56%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.
Wall Road Analyst Weigh In
A number of analysts have not too long ago commented on BMY shares. TD Cowen raised their goal worth on Bristol-Myers Squibb from $53.00 to $59.00 and gave the inventory a “maintain” ranking in a analysis report on Monday, October seventh. Jefferies Monetary Group raised their worth goal on Bristol-Myers Squibb from $49.00 to $51.00 and gave the inventory a “maintain” ranking in a analysis report on Wednesday, August twenty eighth. Citigroup reduce Bristol-Myers Squibb from a “purchase” ranking to a “impartial” ranking and lowered their goal worth for the corporate from $75.00 to $55.00 in a analysis observe on Friday, October twenty fifth. BMO Capital Markets reissued a “market carry out” ranking and issued a $48.00 worth goal on shares of Bristol-Myers Squibb in a analysis report on Monday, September twenty third. Lastly, StockNews.com raised shares of Bristol-Myers Squibb from a “purchase” ranking to a “strong-buy” ranking in a analysis report on Monday, July twenty ninth. One analysis analyst has rated the inventory with a promote ranking, fourteen have issued a maintain ranking and one has issued a robust purchase ranking to the corporate. Based on MarketBeat, Bristol-Myers Squibb presently has a mean ranking of “Maintain” and a mean goal worth of $52.38.
Get Our Newest Analysis Report on BMY
Bristol-Myers Squibb Firm Profile
Bristol-Myers Squibb Firm discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical merchandise worldwide. It affords merchandise for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience illnesses. The corporate’s merchandise embody Eliquis for discount in threat of stroke/systemic embolism in non-valvular atrial fibrillation, and for the remedy of DVT/PE; Opdivo for varied anti-cancer indications, together with bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, abdomen and esophageal most cancers; Pomalyst/Imnovid for a number of myeloma; Orencia for lively rheumatoid arthritis and psoriatic arthritis; and Sprycel for the remedy of Philadelphia chromosome-positive continual myeloid leukemia.
Featured Tales
Obtain Information & Scores for Bristol-Myers Squibb Day by day – Enter your e-mail deal with under to obtain a concise day by day abstract of the most recent information and analysts’ rankings for Bristol-Myers Squibb and associated corporations with MarketBeat.com’s FREE day by day e-mail publication.
